Cargando…

Clinicopathological Characteristics and Prognosis of HER2-Low Early-Stage Breast Cancer: A Single-Institution Experience

BACKGROUND: Human epidermal growth factor 2 (HER2)-low breast cancer, which is defined as HER2 1+ or 2+ in immunohistochemistry without gene amplification, accounts for a considerable part of all breast cancers. However, it remains controversial whether HER2-low breast cancer is a distinct entity. O...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Hangcheng, Han, Yiqun, Wu, Yun, Wang, Yan, Li, Qing, Zhang, Pin, Yuan, Peng, Luo, Yang, Fan, Ying, Chen, Shanshan, Cai, Ruigang, Li, Qiao, Ma, Fei, Xu, Binghe, Wang, Jiayu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245921/ https://www.ncbi.nlm.nih.gov/pubmed/35785207 http://dx.doi.org/10.3389/fonc.2022.906011

Ejemplares similares

In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China
por: Li, Yiqun, et al.
Publicado: (2022)

Sex-Based Heterogeneity in the Clinicopathological Characteristics and Prognosis of Breast Cancer: A Population-Based Analysis
por: Han, Yiqun, et al.
Publicado: (2021)

CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated systematic review and network meta-analysis of 28 randomized controlled trials
por: Xu, Hangcheng, et al.
Publicado: (2022)

Clinicopathological characteristics and prognosis of microinvasive breast cancer: A population‐based analysis
por: Xu, Hangcheng, et al.
Publicado: (2022)

Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis
por: Han, Yiqun, et al.
Publicado: (2019)

The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study
por: Han, Yiqun, et al.
Publicado: (2022)

Risk Factors and Survival of Patients With Liver Metastases at Initial Metastatic Breast Cancer Diagnosis in Han Population
por: Lin, Shaoyan, et al.
Publicado: (2021)

Clinical N3 is an independent risk factor of recurrence for breast cancer patients achieving pathological complete response and near-pathological complete response after neoadjuvant chemotherapy
por: Qian, Xiaoyan, et al.
Publicado: (2022)

Chemotherapy Decision-Making and Survival Outcomes in Older Women With Early Triple-Negative Breast Cancer: Evidence From Real-World Practice
por: Xiu, Meng, et al.
Publicado: (2022)

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A real-world retrospective study in Chinese patients
por: Guo, Jihong, et al.
Publicado: (2019)

Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studies
por: Guan, Xiuwen, et al.
Publicado: (2023)

Clinicopathological Characteristics and Prognosis of Squamous Cell Carcinoma of the Breast: A Population-Based Analysis
por: Han, Yiqun, et al.
Publicado: (2021)

Clinicopathological characteristics and prognosis of breast cancer with special histological types: A surveillance, epidemiology, and end results database analysis
por: Han, Yiqun, et al.
Publicado: (2020)

Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population
por: Wang, Jiayu, et al.
Publicado: (2016)

Real world initial palliative treatment patterns and clinical outcomes in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A study of the National Cancer Center, China
por: Li, Yiqun, et al.
Publicado: (2021)

Phase I safety and pharmacokinetic study of cipatinib, an original dual tyrosine kinase inhibitor
por: Wang, Jiayu, et al.
Publicado: (2018)

A Novel Prognostic Nomogram for Predicting Survival of Hormone Receptor-Positive and HER2 Negative Advanced Breast Cancer Among the Han-Population
por: Zhu, Yimin, et al.
Publicado: (2022)

Timing of paclitaxel treatment in pre‐operative or post‐operative does not affect survival in breast cancer patients
por: Wang, Jiayu, et al.
Publicado: (2017)

The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial–mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer
por: Guan, Xiuwen, et al.
Publicado: (2019)

Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer
por: Guan, Xiuwen, et al.
Publicado: (2023)

Clinicopathological characteristics and prognosis of early-stage HER2 low-expression breast cancer: A single-center retrospective study
por: Liu, Chang-Gen, et al.
Publicado: (2023)

Optimal Choice as First-Line Therapy for Patients with Triple-Negative Breast Cancer: A Bayesian Network Meta-Analysis
por: Han, Yiqun, et al.
Publicado: (2022)

Young breast cancer patients who develop distant metastasis after surgery have better survival outcomes compared with elderly counterparts
por: Wang, Jingjing, et al.
Publicado: (2017)

Vinorelbine Plus Platinum in Patients with Metastatic Triple Negative Breast Cancer and Prior Anthracycline and Taxane Treatment
por: li, Meiying, et al.
Publicado: (2015)

Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapy
por: Li, Meiying, et al.
Publicado: (2018)

Phase II Trial of Goserelin and Exemestane Combination Therapy in Premenopausal Women With Locally Advanced or Metastatic Breast Cancer
por: Wang, Jiayu, et al.
Publicado: (2015)

Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the Han population
por: Mo, Hongnan, et al.
Publicado: (2022)

Epithelial-Mesenchymal-Transition-Like Circulating Tumor Cell-Associated White Blood Cell Clusters as a Prognostic Biomarker in HR-Positive/HER2-Negative Metastatic Breast Cancer
por: Guan, Xiuwen, et al.
Publicado: (2021)

Primary Tumor Surgery for Patients with De Novo Stage IV Breast Cancer can Decrease Local Symptoms and Improve Quality of Life
por: Si, Yiran, et al.
Publicado: (2020)

Tumor Microenvironment Subtypes and Immune-Related Signatures for the Prognosis of Breast Cancer
por: Han, Yiqun, et al.
Publicado: (2021)

Development and validation of a nomogram for predicting survival of advanced breast cancer patients in China
por: Lin, Shaoyan, et al.
Publicado: (2020)

Comparative Efficacy of Tyrosine Kinase Inhibitors and Antibody–Drug Conjugates in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A Systematic Review and Network Meta-Analysis
por: Wang, Yan, et al.
Publicado: (2022)

Construction and Validation of Convenient Clinicopathologic Signatures for Predicting the Prognosis of Stage I-III Gastric Cancer
por: You, Weiqiang, et al.
Publicado: (2022)

Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer
por: Lin, Shaoyan, et al.
Publicado: (2019)

Comparison of capecitabine-based regimens with platinum-based regimens in Chinese triple-negative breast cancer patients with liver metastasis
por: Chen, Yimeng, et al.
Publicado: (2021)

Clinicopathologic Features and Prognosis of BRAF Mutated Colorectal Cancer Patients
por: Guan, Wen-Long, et al.
Publicado: (2020)

Apatinib combined with chemotherapy in patients with previously treated advanced breast cancer: An observational study
por: Zhu, Anjie, et al.
Publicado: (2019)

Incidence, risk factors and survival of patients with brain metastases at initial metastatic breast cancer diagnosis in China
por: Li, Yiqun, et al.
Publicado: (2020)

Establishment and validation of a clinicopathological prognosis model of gastroenteropancreatic neuroendocrine carcinomas
por: Chen, Jing, et al.
Publicado: (2022)

Analysis of the clinicopathological characteristics and prognosis of triple-positive breast cancer and HER2-positive breast cancer—A retrospective study
por: Ma, Dongxu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5t1idea8tjk6659432t2c9fiik